Dendritic-cell immunotherapy:: from ex vivo loading to in vivo targeting

被引：618

作者：

Tacken, Paul J. ^{[1
]}

de Vries, I. Jolanda M. ^{[1
]}

Torensma, Ruurd ^{[1
]}

Figdor, Carl G. ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Med Ctr, NL-6500 HB Nijmegen, Netherlands

来源：

NATURE REVIEWS IMMUNOLOGY | 2007年 / 7卷 / 10期

关键词：

D O I：

10.1038/nri2173

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The realization that dendritic cells (DCs) orchestrate innate and adaptive immune responses has stimulated research on harnessing DCs to create more effective vaccines. Early clinical trials exploring autologous DCs that were loaded with antigens ex vivo to induce T-cell responses have provided proof of principle. Here, we discuss how direct targeting of antigens to DC surface receptors in vivo might replace laborious and expensive ex vivo culturing, and facilitate large - scale application of DC-based vaccination therapies.

引用

页码：790 / 802

页数：13

共 152 条

[1] Chloroquine enhances human CD8+ T cell responses against soluble antigens in vivo [J].

Accapezzato, D ;

Visco, V ;

Francavilla, V ;

Molette, C ;

Donato, T ;

Paroli, M ;

Mondelli, MU ;

Doria, M ;

Torrisi, MR ;

Barnaba, V .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 202 (06) :817-828

[2] Access of soluble antigens to the endoplasmic reticulum can explain cross-presentation by dendritic cells [J].

Ackerman, AL ;

Kyritsis, C ;

Tampé, R ;

Cresswell, P .

NATURE IMMUNOLOGY, 2005, 6 (01) :107-113

[3] Migration of dendritic cell based cancer vaccines:: in vivo veritas? [J].

Adema, GJ ;

de Vries, IJM ;

Punt, CJA ;

Figdor, CG .

CURRENT OPINION IN IMMUNOLOGY, 2005, 17 (02) :170-174

[4] Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835] [J].

Apostolopoulos, Vasso ;

Pietersz, Geoffrey A. ;

Tsibanis, Anastasios ;

Tsikkinis, Annivas ;

Drakaki, Heleni ;

Loveland, Bruce E. ;

Piddlesden, Sara J. ;

Plebanski, Magdalena ;

Pouniotis, Dodie S. ;

Alexis, Michael N. ;

McKenzie, Ian F. ;

Vassilaros, Stamatis .

BREAST CANCER RESEARCH, 2006, 8 (03)

[5]

Banchereau J, 2001, CANCER RES, V61, P6451

[6] Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon [J].

Banchereau, J ;

Ueno, H ;

Dhodapkar, M ;

Connolly, J ;

Finholt, JP ;

Klechevsky, E ;

Blanck, JP ;

Johnston, DA ;

Palucka, AK ;

Fay, J .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (05) :505-516

[7] Dendritic cells and the control of immunity [J].

Banchereau, J ;

Steinman, RM .

NATURE, 1998, 392 (6673) :245-252

[8] An altered T cell repertoire in MECL-1-deficient mice [J].

Basler, Michael ;

Moebius, Jacqueline ;

Elenich, Laura ;

Groettrup, Marcus ;

Monaco, John J. .

JOURNAL OF IMMUNOLOGY, 2006, 176 (11) :6665-6672

[9] Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma [J].

Batchu, RB ;

Moreno, AM ;

Szmania, SM ;

Bennett, G ;

Spagnoli, GC ;

Ponnazhagan, S ;

Barlogie, B ;

Tricot, G ;

van Rhee, F .

CANCER RESEARCH, 2005, 65 (21) :10041-10049

[10] Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after FcγRII-mediated uptake [J].

Benitez-Ribas, Daniel ;

Adema, Gosse J. ;

Winkels, Gregor ;

Klasen, Ina S. ;

Punt, Cornelis J. A. ;

Figdor, Carl G. ;

de Vries, I. Jolanda M. .

JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (07) :1629-1635

← 1 2 3 4 5 6 7 8 9 10 →